SVB Securities analyst Andrew Berens maintained a Buy rating on Compass Therapeutics (CMPX – Research Report) on March 15 and set a price target of $11.00. The company’s shares opened today at $3.40.
Berens covers the Healthcare sector, focusing on stocks such as AstraZeneca, Seagen, and Zymeworks. According to TipRanks, Berens has an average return of -0.6% and a 43.78% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Compass Therapeutics with a $8.75 average price target, representing a 157.35% upside. In a report released on March 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
Based on Compass Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.98 million. In comparison, last year the company had a GAAP net loss of $12.98 million
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CMPX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Its pipeline product candidates are CTX-471/ CD137 agonist and CTX-8371.
Read More on CMPX:
- Compass Therapeutics expects cash to fund operations into 2026
- Compass Therapeutics reports Q4 EPS (10c), consensus (11c)
- Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference
- Compass Therapeutics initiated with a Buy at Jefferies
